Overview

* BioAtla ( BCAB ) Q3 net loss widens to $15.8 mln, driven by absence of collaboration revenue

* R&D expenses decreased due to program prioritization and workforce reduction

* Company in advanced stages to finalize strategic transaction by year-end

Outlook

* BioAtla ( BCAB ) expects to complete a strategic partnership by year end

Result Drivers

* Research and development (R&D) expenses were $9.5 million for the quarter ended September 30, 2025, compared to $16.4 million for the same quarter in 2024.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$15.78

Income mln

Q3 $13.79

Operatin mln

g

Expenses

Q3 -$13.79

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Bioatla Inc ( BCAB ) is $10.00, about 93.1% above its November 12 closing price of $0.69

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)